Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | MMP7 | P09237 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032958 | 0.79 | ALDH1A1 (0.43) | ALDH1A1GAAMMP1MMP3MMP7 | |
| SCHEMBL4041586 | 0.76 | FKBP1A (0.41) | ALDH1A1MMP1MMP3MMP7MMP9 | |
| SCHEMBL4036533 | 0.72 | MMP3 (0.43) | ALDH1A1MMP1MMP3MMP7MMP9 | |
| SCHEMBL4033188 | 0.71 | ALDH1A1 (0.46) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL4038075 | 0.69 | ALDH1A1 (0.47) | ALDH1A1GAALMNAUSP2HTT | |
| SCHEMBL17833176 | 0.69 | MMP2 (0.59) | ALDH1A1GAAMMP9LMNAHTT | |
| SCHEMBL695071 | 0.69 | MMP2 (0.59) | ALDH1A1GAAMMP9LMNAHTT | |
| SCHEMBL2886117 | 0.68 | MMP1 (0.62) | ALDH1A1GAAMMP1MMP3MMP7 | |
| SCHEMBL8718942 | 0.68 | LMNA (0.58) | ALDH1A1MMP9LMNAUSP2HTT | |
| SCHEMBL5635689 | 0.67 | MMP9 (0.52) | ALDH1A1GAAMMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | ALDH1A1 610/4885GAA 4649/4885MMP1 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.